Minor
REPIFIR · Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab · Relapse/Refractory Large B Cell Lymphoma
Trial sites expanded: 15 → 19 locations
Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaPhase 2 NCT07126236 Registry history of NCT07126236 on ClinicalTrials.gov (opens the registry)